Cumberland Pharmaceuticals Inc. Aktie News

Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Tr...

Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn. , Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to ta...

Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn. , Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico.

Vibativ ®  treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia , Sept.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants A. J. Kazimi - Founder, Chairman, President & CEO John Michael Hamm - VP & CFO Todd M.

NASHVILLE, Tenn. , Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period.

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers NASHVILLE, Tenn. , Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced the availability of the Vibativ® (telavancin) 4-Vial Starter Pak through a new...